Objectives: Ceftolozane/tazobactam is a novel b-lactam b-lactamase inhibitor combination with a broad spectrum of activity that includes Pseudomonas aeruginosa. The purpose of this study was to evaluate the in vitro activity of ceftolozane/tazobactam and relevant comparators versus a large collection of antimicrobial non-susceptible P. aeruginosa clinical isolates recovered from patients across Canada (CANWARD, 2008-16).
Introduction
Ceftolozane/tazobactam is a novel b-lactam b-lactamase inhibitor combination with excellent in vitro activity against a diverse range of Gram-negative bacilli, including Pseudomonas aeruginosa.
1,2
This antimicrobial is able to circumvent many of the common resistance mechanisms present in P. aeruginosa, supporting a possible role in the treatment of infections caused by antimicrobialresistant P. aeruginosa isolates, including MDR strains. [3] [4] [5] [6] The purpose of this study was to evaluate the in vitro activity of ceftolozane/tazobactam and relevant comparators against a large collection of antimicrobial non-susceptible P. aeruginosa clinical isolates obtained from patients across Canada as part of the CANWARD study. As ceftolozane/tazobactam has only recently been approved for use in Canada, surveillance data from this country provide a baseline of in vitro activity versus a treatment-naive set of isolates.
Methods

Bacterial isolates
From January 2008 to December 2016, inclusive, 10-15 sentinel hospitals across Canada submitted clinical isolates from patients attending V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. emergency rooms, medical and surgical wards, hospital clinics and intensive care units (CANWARD). On an annual basis, each centre was asked to submit clinical isolates (consecutive, one per patient/infection site) from blood, respiratory tract, urine and wound infections. The medical centres submitted clinically significant isolates, as defined by their local site criteria. Isolate identification was performed by the submitting site and confirmed at the reference site as required (i.e. when morphological characteristics and antimicrobial susceptibility patterns did not fit the reported identification). Isolates were shipped on Amies semi-solid transport media to the coordinating laboratory (Health Sciences Centre, Winnipeg, Canada), subcultured onto appropriate media and stocked in skim milk at #80 C until MIC testing was carried out.
Antimicrobial susceptibilities
Following two subcultures from frozen stock, the in vitro activity of ceftolozane/tazobactam and relevant comparators was determined by broth microdilution in accordance with the CLSI guidelines. 7, 8 In-house-prepared 96-well broth microdilution panels were used to test all antimicrobial agents. Antimicrobial MICs were interpreted using CLSI breakpoints. 7 The current ceftolozane/tazobactam CLSI breakpoints for P. aeruginosa are 4/4 mg/L (susceptible), 8/4 mg/L (intermediate) and 16/4 mg/L (resistant). 7 Ceftolozane was evaluated with a fixed concentration of tazobactam (4 mg/L). MDR P. aeruginosa isolates were defined as isolates testing nonsusceptible to at least one antimicrobial from three or more different classes. XDR P. aeruginosa isolates were defined as a subset of MDR isolates that tested non-susceptible to at least one antimicrobial from five different classes. For the purpose of this report, the five antimicrobial classes considered were aminoglycosides (gentamicin and amikacin), fluoroquinolones (ciprofloxacin), antipseudomonal cephalosporins (ceftazidime), antipseudomonal penicillins (piperacillin/tazobactam) and carbapenems (meropenem). Colistin was not used in the classification of MDR or XDR isolates.
Results
In total, 3229 P. aeruginosa clinical isolates were obtained as a part of the CANWARD study between January 2008 and December 2016. Isolates were collected from patients in medical wards (n " 1087, 33.7%), hospital clinics (n " 775, 24.0%), intensive care units (n " 760, 23.5%), emergency rooms (n " 375, 11.6%) and surgical wards (n " 232, 7.2%). The distribution of isolates by specimen source was 2183 (67.6%) respiratory, 572 (17.7%) blood, 333 (10.3%) wound and 141 (4.4%) urine. The in vitro activity of ceftolozane/tazobactam and comparators versus all isolates and antimicrobial non-susceptible subsets is presented in Table 1 . The MIC distribution of ceftolozane/tazobactam versus antimicrobialsusceptible and antimicrobial non-susceptible isolates is presented in Table 2 . Ceftolozane/tazobactam was the most active antimicrobial evaluated versus the collection of isolates, with 98.3% testing susceptible (Table 1) . Ceftolozane/tazobactam demonstrated good in vitro activity versus isolate subsets that were non-susceptible to different antipseudomonal antimicrobials (Tables 1 and 2) .
Four-hundred and sixty-two P. aeruginosa isolates were MDR (14.3% of all isolates tested). Ceftolozane/tazobactam demonstrated excellent in vitro activity versus the MDR isolates, with 90.5% remaining susceptible. In contrast, fewer than 25% of MDR isolates tested susceptible to the antipseudomonal b-lactams ceftazidime, meropenem and piperacillin/tazobactam. Eighty-four P. aeruginosa isolates met the definition of XDR (2.6% of all isolates tested). These isolates were all non-susceptible to ciprofloxacin, ceftazidime, meropenem and piperacillin/tazobactam. Despite the significant in vitro resistance demonstrated by this subset, 78.6% of XDR isolates remained susceptible to ceftolozane/tazobactam.
Discussion
Other large surveillance studies have similarly evaluated the in vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible P. aeruginosa.
9,10 Farrell et al. 9 described the activity of ceftolozane/tazobactam versus 1971 P. aeruginosa clinical isolates from patients in US hospitals. Overall, 96.1% of isolates were susceptible to ceftolozane/tazobactam, applying the current CLSI P. aeruginosa breakpoint. The percentages of MDR and XDR isolates (classified per standard definitions) that remained susceptible to ceftolozane/tazobactam were 79.0% and 70.9%, respectively. 9, 11 The results of that study are in agreement with the data presented here. In contrast, only 84.5% of 2191 P. aeruginosa clinical isolates from centres in Europe (plus Turkey and Israel) were susceptible to ceftolozane/tazobactam (CLSI breakpoint) in a recent study by Sader et al. 10 Additionally, only 53.2% and 42.8% of MDR and XDR P. aeruginosa isolates (standard definitions) described in this publication remained susceptible to ceftolozane/ tazobactam. 10, 11 The significantly lower ceftolozane/tazobactam susceptibility among European MDR and XDR P. aeruginosa isolates relative to those from Canada likely relates to differences in commonly circulating resistance mechanisms. Sader et al.
10 evaluated 139 of their ceftolozane/tazobactam-resistant isolates and found that 71.9% carried a VIM-like metallo-b-lactamase gene. In Canada, metallo-b-lactamase enzymes are uncommon among P. aeruginosa.
12
Published clinical experience with the use of ceftolozane/ tazobactam for the treatment of antimicrobial-resistant P. aeruginosa infections remains limited to case reports and small case series. [13] [14] [15] [16] [17] [18] Dinh et al. 15 reported the use of ceftolozane/ tazobactam as salvage therapy for 15 patients with infection due to XDR P. aeruginosa (defined as non-susceptible to all but two or fewer antimicrobial categories). All infecting strains were susceptible in vitro to ceftolozane/tazobactam. The most common site of infection was the respiratory tract (47% of cases) and ceftolozane/ tazobactam was used in combination with another active antibacterial agent in 67% of patients. Overall, clinical cure was observed in 10 of 15 patients (67%), while all-cause in-hospital mortality was 27%. 15 Caston et al. 16 described use of ceftolozane/tazobactam in the treatment of 12 patients with infection due to an MDR P. aeruginosa isolate (MDR defined as resistance to at least three antimicrobial classes). All isolates were ceftolozane/ tazobactam susceptible. Half of the patients had pneumonia and 10 of 12 presented with septic shock. Clinical cure was documented in 75% of patients (9 of 12). The patient mortality during follow-up was 25%. 16 Munita et al. 17 reviewed the outcome of patients who received ceftolozane/tazobactam for the treatment of carbapenem-resistant P. aeruginosa infections at six hospitals in the United States. The most common diagnosis was pneumonia. Among 30 isolates for which susceptibility testing was performed, 26 (87%) were fully susceptible to ceftolozane/tazobactam. Ceftolozane/tazobactam was administered as monotherapy to 27 patients (77%). Overall, treatment was considered successful in 74% (26 of 35). Among the nine cases of clinical failure, four occurred in patients infected with a ceftolozane/tazobactam non-susceptible isolate. 17 Finally, Haidar et al. 18 reported on the Walkty et al. 
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Ceftolozane/tazobactam for non-susceptible P. aeruginosa JAC use of ceftolozane/tazobactam for the treatment of 21 patients with infection due to MDR P. aeruginosa (non-susceptibility to at least three antimicrobial classes). The most common focus of infection was the respiratory tract (86%, 18 of 21) and combination therapy was frequently used. In this series, treatment success was 71%. Thirty day all-cause and attributable mortality rates were 10% and 5%, respectively. Of concern, ceftolozane/tazobactam resistance emerged in three patients (14%). 18 The data presented in these small series are encouraging. However, the retrospective, non-comparative nature of the studies and small numbers of patients make it difficult to draw firm conclusions regarding the clinical efficacy of ceftolozane/tazobactam for antimicrobial-resistant P. aeruginosa infections. In areas where metallo-b-lactamase enzymes are common, it is anticipated that ceftolozane/tazobactam may be less useful.
There are several important limitations to this study that should be recognized. The internationally recommended definition for XDR P. aeruginosa could not be strictly applied as certain relevant antimicrobials (aztreonam, fosfomycin) were not included on the susceptibility testing panels. 11 However, all of the XDR P. aeruginosa isolates in this study were susceptible to two or fewer antipseudomonal agents; thus, it is likely they also met the international definition. The mechanisms causing resistance to ceftolozane/tazobactam and other antipseudomonal antimicrobials were not investigated. In Canada, metallo-b-lactamase production among P. aeruginosa remains relatively uncommon, and the presumed rarity of this resistance mechanism is supported by the high susceptibility rate to ceftolozane/tazobactam. 12 As metallob-lactamase production would be expected to compromise the activity of this antimicrobial, the susceptibility data presented here Walkty et al.
may be less relevant for countries where metallo-b-lactamase enzymes are more prevalent. Finally, related to limited space on the antimicrobial susceptibility testing panels, several clinically important antipseudomonal antimicrobials (cefepime, doripenem, tobramycin) were not included in the study.
In conclusion, ceftolozane/tazobactam demonstrated excellent in vitro activity versus antimicrobial non-susceptible P. aeruginosa clinical isolates, including MDR and XDR subsets in this large Canadian surveillance study. These data suggest that this antimicrobial may be useful in the treatment of infections caused by antimicrobial non-susceptible P. aeruginosa. The utility of ceftolozane/tazobactam in treating antimicrobial non-susceptible P. aeruginosa infections is further supported by limited published clinical series, although further data are needed. Ongoing surveillance of P. aeruginosa susceptibility to ceftolozane/tazobactam will be of critical importance as use of this antimicrobial increases, to monitor for the emergence of resistance. Ceftolozane/tazobactam for non-susceptible P. aeruginosa JAC
